Loading...

Supernus Pharmaceuticals, Inc.

0LB2.L•LSE
Healthcare
Medical - Pharmaceuticals
£45.00
£2.00(4.65%)

Supernus Pharmaceuticals, Inc. (0LB2.L) Stock Overview

Explore Supernus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.5/100

Key Financials

Market Cap2.5B
P/E Ratio38.64
EPS (TTM)$1.31
ROE0.06%
Fundamental Analysis

AI Price Forecasts

1 Week$30.92
1 Month$32.56
3 Months$31.56
1 Year Target$37.39

0LB2.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Supernus Pharmaceuticals, Inc. (0LB2.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.14, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $37.39.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 38.64 and a market capitalization of 2.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-5.52%
5-Day Change
-1.24%
1-Month Change
-3.47%
3-Month Change
-19.95%
6-Month Change
-8.46%
Year-to-Date (YTD) Change
-16.60%
1-Year Change
-6.80%
3-Year Change
-7.57%
5-Year Change
24.19%
All-Time (Max) Change
-26.92%

Contact Information

https://www.supernus.com
301 838 2500
9715 Key West Avenue, Rockville, MD, 20850

Company Facts

674 Employees
IPO DateJan 29, 2018
CountryUS
Actively Trading

Frequently Asked Questions

;